SNOTF yields 9.09% · JNJ yields 2.13%● Live data
📍 SNOTF pulled ahead of the other in Year 1
Combined, SNOTF + JNJ cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of SNOTF + JNJ for your $10,000?
Sinotrans Limited provides integrated logistics services primarily in the People's Republic of China. The company operates through three segments: Forwarding and Related Business, Logistics, and E-commerce. It offers sea freight forwarding, such as space booking, arranging transportation, container delivery and loading, storage, port concentration and dispatch, customs declaration and inspection, distribution, and delivery; air freight forwarding, including pick-up and dispatch, warehousing, packaging, booking and handling, trunk air line freight forwarding, and trucking transit services; rail freight forwarding services; shipping agency services comprising port arrival and departure, documentation, ship supplies, and other ship related services at ports; and storage and terminal services, such as storage, container consolidating and devanning, cargo loading and unloading, dispatching and distribution, etc. The company also engages in the e-commerce business consisting of cross-border e-commerce logistics, logistics e-commerce platform, and logistics equipment sharing platform. In addition, it provides integrated logistics solutions, including contract, project, chemical, cold chain, and other logistics services; whole supply chain logistics services; and supply chain management services. Sinotrans Limited was founded in 1950 and is based in Beijing, the People's Republic of China.
Full SNOTF Calculator →Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.
Full JNJ Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.